CN102614155B - Mixed litholytic agent for dissolving cholesterol stone - Google Patents
Mixed litholytic agent for dissolving cholesterol stone Download PDFInfo
- Publication number
- CN102614155B CN102614155B CN 201210065192 CN201210065192A CN102614155B CN 102614155 B CN102614155 B CN 102614155B CN 201210065192 CN201210065192 CN 201210065192 CN 201210065192 A CN201210065192 A CN 201210065192A CN 102614155 B CN102614155 B CN 102614155B
- Authority
- CN
- China
- Prior art keywords
- lecithin
- cholesterol
- butyl ether
- agent
- lithodialysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a mixed litholytic agent for dissolving cholesterol stone. The mixed litholytic agent is characterized by containing methyl tertiary butyl ether and lecithin; and based on 1mL of methyl tertiary butyl ether, the lecithin is 0.10-0.60g and is soya bean lecithin or egg yolk lecithin preferably. The mixed litholytic agent can correspondingly reduce saturated steam pressure of the methyl tertiary butyl ether, and because the percentage of the methyl tertiary butyl ether is correspondingly reduced, the irritation of odor of the methyl tertiary butyl ether is correspondingly reduced; therefore, the novel litholytic agent can be used for treating clinical patients with cholesterol stone through non-operative treatment.
Description
Technical field
The present invention relates to a kind of novel mixing lithodialysis agent that is used for dissolving cholesterol type calculus.
Background technology
Along with growth in the living standard, the sickness rate of cholelithiasis raises year by year, according to statistics, crowd about 10% is arranged at present in the misery of standing calculus and bringing both at home and abroad, therefore explores the Iithiasic method of a kind of effective treatment when must be anxious.
At present the excision gallbladder is the Main Means for the treatment of cholelithiasis, but cholecystectomy not only medical expense is high, operation risk is large, excising simultaneously gallbladder can bring some inconvenience to people's life from now on.In addition, some patients such as old, fat and suffer from other important organ diseases, are not fit to carry out the treatment of cholecystectomy, and therefore, the Iithiasic method of development non-operative treatment is significant.
Oral drug therapy is ideal Therapeutic Method, and since nineteen thirty-seven Neubridge attempted treating calculus with the method for oral bile acid, some other medicine was also by developing in succession, such as chenodeoxy cholic acid, ursodeoxycholic acid, Pravastatin, Chinese herbal and crude drugs preparations etc.But in general, the oral drugs lithodialysis has weak curative effect, and the course for the treatment of is long, and expense is high, and the shortcomings such as relapse rate height are demanded further development urgently.
Directly litholysis also is the Iithiasic method of a kind of comparatively desirable treatment, owing to put pipe (PTCD) or through approach such as endoscopic retrograde gallbladder intubate (ERCG) by percutaneous through transhepatic cholangiography, lithodialysis agent perfusion enters gallbladder, can directly contact with cholelithiasis, therefore direct litholysis treatment time weak point, it is fast to produce effects.But the popularization of this Therapeutic Method need to be sought a kind of lithodialysis agent to human-body safety.Ether is the lithodialysis agent that is employed the earliest, but because the ether boiling point is lower than body temperature, advance in the human body after vaporization and produce high pressure, make patient produce tormina and be not widely accepted.Dextrorotation hesperidene subsequently, Capmul MCM C8, propionic acid ethyl etc. are used as the lithodialysis agent of direct litholysis in succession, but more or less there are the problems such as the not high or toxic and side effects of lithodialysis rate is large in they and are not further used.
At present, the most effectively the lithodialysis agent is methyl tert-butyl ether, and its litholytic effect is strong 50 times than caprylin, is 90～96% to the complete lithodialysis rate of cholesterol gallstones.Since methyl tert-butyl ether was used as the lithodialysis agent, lot of domestic and international scholar had carried out relevant research to the toxic and side effects of methyl tert-butyl ether, and experimental result shows that methyl tert-butyl ether is to being safe on the human body basic.But methyl tert-butyl ether also exists certain defective as the lithodialysis agent, although be 55.7 ℃ such as the boiling point of methyl tert-butyl ether, is higher than people's body temperature, and the volatility of methyl tert-butyl ether is more intense, still has volatilization when being applied to human body and produces this problem of high pressure.Simultaneously, methyl tert-butyl ether can produce and make the very uncomfortable penetrating odor of people.
Summary of the invention
In order to overcome the problems referred to above of existing lithodialysis agent, the inventor studies discovery, by in methyl tert-butyl ether, adding lecithin, saturated vapor pressure that not only can corresponding reduction methyl tert-butyl ether, and owing to reduced comparatively speaking the percentage composition of methyl tert-butyl ether, therefore the also corresponding zest that reduces its abnormal smells from the patient, thus a kind of novel mixing lithodialysis agent that is used for dissolving cholesterol type calculus obtained, finished on this basis the present invention.
Therefore, theme of the present invention provides a kind of mixing lithodialysis agent for dissolving cholesterol type calculus, and it comprises methyl tert-butyl ether and lecithin, and based on the methyl tert-butyl ether meter of 1mL, the amount of lecithin is 0.10～0.60g, and described lecithin is soybean lecithin or Ovum Gallus domesticus Flavus lecithin preferably.
The inventor has carried out lot of experiments to the dissolving situation of cholesterol, found that, along with the increase of lecithin addition, mixed solution increases gradually to the meltage of cholesterol in a certain amount of methyl tert-butyl ether, and the abnormal smells from the patient of mixed solution then diminishes gradually.
Take soybean lecithin as example, when the amount of soybean lecithin for the methyl tert-butyl ether of 1mL was 0.10g, mixed solution did not have to increase more than 20% in the soybean lecithin situation to the meltage ratio of cholesterol.Along with the increase of soybean lecithin addition in the mixed solution, the originally gradually increase of meltage to cholesterol slowly reaches a peak, then decreases again.When being 0.30g such as the amount when soybean lecithin for the methyl tert-butyl ether of 1mL, mixed solution does not have to increase about 50% in the soybean lecithin situation to the meltage ratio of cholesterol; When the amount of soybean lecithin for the methyl tert-butyl ether of 1mL was 0.40g, mixed solution did not have to increase in the soybean lecithin situation about 64% to the meltage ratio of cholesterol, almost reach a relative maximum; But when the amount of soybean lecithin for the methyl tert-butyl ether of 1mL is 0.50g, although mixed solution does not have to increase about 50% in the soybean lecithin situation to the meltage ratio of cholesterol, decrease than maximum; And when the amount of soybean lecithin for the methyl tert-butyl ether of 1mL was 0.60g, mixed solution did not have to increase more than 20% in the soybean lecithin situation to the meltage ratio of cholesterol.
Take Ovum Gallus domesticus Flavus lecithin as example, when the amount of Ovum Gallus domesticus Flavus lecithin for the methyl tert-butyl ether of 1mL was 0.10g, mixed solution did not have to increase about 62% in the Ovum Gallus domesticus Flavus lecithin situation to the meltage ratio of cholesterol.Increase along with mixed solution mesolecithal lecithin addition, meltage to cholesterol slightly increases, but not obvious, when being 0.20g, 0.30g and 0.40g such as the amount when Ovum Gallus domesticus Flavus lecithin for the methyl tert-butyl ether of 1mL, mixed solution does not have to increase respectively in the Ovum Gallus domesticus Flavus lecithin situation about 64%, 67% and 74% to the meltage ratio of cholesterol; And when the amount of Ovum Gallus domesticus Flavus lecithin for the methyl tert-butyl ether of 1mL was 0.50g, mixed solution did not have to increase nearly 1 times in the Ovum Gallus domesticus Flavus lecithin situation to the meltage ratio of cholesterol.
Be not bound by any theory, why the agent of described mixing lithodialysis above-mentioned dissolution phenomena occurs to cholesterol, mainly be because, the inventor finds, lecithin such as soybean lecithin or Ovum Gallus domesticus Flavus lecithin produce solubilization to cholesterol, when lecithin in the methyl tert-butyl ether such as soybean lecithin or the increase of Ovum Gallus domesticus Flavus lecithin addition, mixed solution can increase gradually to the meltage of cholesterol, but the viscosity of mixed solution also increases gradually simultaneously.And viscosity increase degree is different according to circumstances, and for soybean lecithin, the viscosity increase causes the speed of dissolving cholesterol to slow down to some extent, and therefore after dissolubility reached relative peak, the viscosity of increase had hindered the dissolving of cholesterol to a certain extent; And in the Ovum Gallus domesticus Flavus lecithin situation, the impact that dissolubility is increased by viscosity is little, thereby shows as along with the Ovum Gallus domesticus Flavus lecithin addition increases, and the meltage of cholesterol is also increasing always.
Although in fact when the dissolution time long enough, the content of lecithin such as soybean lecithin or Ovum Gallus domesticus Flavus lecithin is higher in the lithodialysis agent, its meltage to cholesterol is larger.But in actual applications, we not only will consider the lithodialysis agent of unit volume to the meltage of cholelithiasis, need consider that also the lithodialysis agent is to dissolution velocity and the Cost Problems of cholelithiasis.
Therefore, according to the present invention, described mixing lithodialysis agent for dissolving cholesterol type calculus, based on the methyl tert-butyl ether meter of 1mL, lecithin, the amount of preferably soya lecithin or Ovum Gallus domesticus Flavus lecithin is 0.10～0.60g, preferred 0.20～0.50g, more preferably 0.3～0.4g.The optimum amount of lecithin is different according to circumstances in the lithodialysis agent of selecting in actual applications, as for soybean lecithin and methyl tert-butyl ether the relationship between quantities, methyl tert-butyl ether meter based on 1mL, the amount of soybean lecithin most preferably is 0.30～0.40g, and the amount of Ovum Gallus domesticus Flavus lecithin most preferably is 0.10～0.40g.
According to the preferred embodiment of the present invention, described lithodialysis agent becomes branch to form by two kinds of the methyl tert-butyl ether of the above amount and lecithin such as soybean lecithin or Ovum Gallus domesticus Flavus lecithins.
Another theme of the present invention is the purposes that the above lithodialysis agent is used for dissolving cholesterol type calculus.
Another theme of the present invention is the purposes of the above lithodialysis agent in the medicine of preparation treatment cholesterol type calculus.
With lithodialysis agent of the present invention the cholesterol type calculus is carried out dissolution in vitro, found that cholelithiasis is dissolved substantially, only stay a small amount of insoluble residue.By in the ultrared spectrum storehouse to the infrared spectrum matching ratio of residue pair, find the infrared spectrum and bilirubinic spectrogram matching degree maximum of residue.And reported once in the pertinent literature that the main component in people's cholelithiasis was cholesterol and bilirubin, and cholesterol level surpasses 70% in the cholesterol type calculus, have in addition up to more than 90%.Therefore, lithodialysis agent of the present invention is better for the litholytic effect of cholesterol type calculus.Although lithodialysis agent according to the present invention is not good to bilirubinic solute effect, but the cholesterol type calculus is dissolved rear last residue diameter substantially basically less than 1mm, and directly in the gallstone dissolution with infusion operation employed conduit diameter generally about 2mm, the average diameter of bile duct probably is 2 to 3mm, therefore these insoluble residues are enough little, fully can be extracted out or be gone out by biliary system by conduit.
Lithodialysis agent of the present invention can be adopted the administering mode of direct litholysis, put pipe (PTCD) or through approach such as endoscopic retrograde gallbladder intubate (ERCG) by percutaneous through transhepatic cholangiography, lithodialysis agent perfusion is entered gallbladder, it is directly contacted with cholelithiasis, the cholesterol type calculus is demonstrated obvious curative effects, except having given play to direct litholysis treatment time weak point, the fast effect of producing effects, the stomachache sense that the high pressure of also having avoided vaporization or volatilization to produce brings to patient, also corresponding penetrating odor and other side effect that has reduced methyl tert-butyl ether.
The experiment in vitro that novel lithodialysis agent of the present invention is used for the dissolving human gallstones studies show that this novel lithodialysis agent is better than any lithodialysis agent on the market to the solvability of human gallstones.Because the lecithin such as soybean lecithin and Ovum Gallus domesticus Flavus lecithin are health promoting products, to human body without any toxicity, document in conjunction with in the past relevant methyl tert-butyl ether toxicity research, owing to reach the consumption that same litholytic effect has correspondingly reduced methyl tert-butyl ether, the abdominal part distending pain sense that can suppress its volatilization to a certain extent and may bring thus, weakened simultaneously its penetrating odor, therefore novel lithodialysis agent of the present invention can be used in the treatment of clinical cholesterol type calculus patient's non-operative treatment fully.
Description of drawings
Fig. 1: the infrared spectrogram of cholelithiasis sample and cholesterol standard infrared spectrogram, wherein upper figure is the cholelithiasis sample spectra, figure below is the cholesterol standard spectrum;
The electromicroscopic photograph of remaining insoluble residue after the lithodialysis agent dissolving of cholelithiasis sample through comprising methyl tert-butyl ether and soybean lecithin among Fig. 2: the embodiment 2;
Fig. 3: the infrared spectrogram of cholelithiasis sample and cholelithiasis be the fully comparison of the infrared spectrogram of the rear last residue of dissolving in the lithodialysis agent of embodiment 2, and wherein upper figure is the cholelithiasis sample spectra, and figure below is the infrared spectrum of last residue after the dissolving;
Fig. 4: cholelithiasis is implemented the front photo of lithodialysis agent dissolving of example 2;
Fig. 5: the photo after the lithodialysis agent that cholelithiasis is implemented example 2 is fully dissolved;
Fig. 6: cholelithiasis is implemented the front photo of lithodialysis agent dissolving of example 4;
Fig. 7: the photo after the lithodialysis agent that cholelithiasis is implemented example 4 is fully dissolved;
Fig. 8 a: be the structural formula of methyl tertiary butyl ether(MTBE), wherein the carbon atom at methyl is marked with *;
Fig. 8 b: be the structural formula of cholesterol, wherein * be marked on the corresponding carbon atom of position as shown in the figure;
After Fig. 8 c:MTBE dissolving cholesterol, with the corresponding nuclear-magnetism of the carbon atom of * spectrum, wherein peak is labeled as the b peak in the cholesterol; Embodiment 2 prepare lithodialysis agent dissolving cholesterol after, with the corresponding nuclear-magnetism of the carbon atom of * spectrum, wherein peak is labeled as a peak in the cholesterol; With
After Fig. 8 d:MTBE dissolving cholesterol, with the corresponding nuclear-magnetism of the carbon atom of * spectrum, wherein peak is labeled as the b peak in the cholesterol; Embodiment 5 prepare lithodialysis agent dissolving cholesterol after, with the corresponding nuclear-magnetism of the carbon atom of * spectrum, wherein peak is labeled as a peak in the cholesterol.
The specific embodiment
The present invention is described in detail by the specific embodiment below in conjunction with accompanying drawing.Characteristics of the present invention and advantage will become more clear, clear and definite along with these descriptions.
Embodiment 1:
The agent of preparation lithodialysis:
In order to measure the different lithodialysis agent of soybean lecithin amount at the appointed time to the solvability of cholesterol, the methyl tert-butyl ether that adds respectively 3mL in the color-comparison tube of 6 10mL, add respectively again 0.00g, 0.30g, 0.60g, 0.90g, 1.20g, the soybean lecithin of 1.50g is made solution.
Dissolving cholesterol:
Add gradually cholesterol in these 6 test tubes, vortex oscillation was calculated respectively the meltage of cholesterol after 3 minutes.
Experimental result:
Listed in the table 1 and increased the dissolving situation of cholesterol in this lithodialysis agent along with the soybean lecithin amount.
Table 1:
| The amount of methyl tert-butyl ether (mL) | 3 | 3 | 3 | 3 | 3 | 3 |
| The amount of soybean lecithin (g) | 0.00 | 0.30 | 0.60 | 0.90 | 1.20 | 1.50 |
| The amount of dissolving cholesterol (g) | 0.42 | 0.51 | 0.51 | 0.60 | 0.69 | 0.63 |
Can find out that from the experimental result of table 1 along with the content of soybean lecithin increases, the amount of dissolving cholesterol increases gradually in the lithodialysis agent, when the mass penalty of soybean lecithin during to 1.5g, the meltage of cholesterol in the lithodialysis agent reduces on the contrary.
Embodiment 2:
The agent of preparation lithodialysis:
This relation preparation lithodialysis agent of soybean lecithin according to the corresponding 0.90g of the methyl tert-butyl ether of 3mL.
The dissolving human gallstones:
Get a cholelithiasis sample that takes out from human body, its infrared spectrum is shown in the figure above among Fig. 1, and following figure is cholesterol standard infrared spectrogram.Determine that by Fig. 1 this sample is the cholesterol type calculus.Form photo before this cholelithiasis is dissolved by the lithodialysis agent as described in Figure 4.
This cholelithiasis sample is added in the lithodialysis agent of preparing gradually, and ultrasonic lower, cholelithiasis is dissolved substantially after 14 to 15min, only stays a small amount of insoluble residue.
Residue is carried out electronic microscope photos, and its electromicroscopic photograph shows that the diameter of residue is basically less than 1mm as shown in Figure 2.And employed conduit diameter was about 2mm during directly gallstone dissolution with infusion was performed the operation, and the average diameter of bile duct is 2 to 3mm, so these insoluble residues are enough little, fully can be extracted out or be gone out by biliary system by conduit.
Fig. 3 is infrared spectrogram and cholelithiasis fully comparison of the infrared spectrogram of the rear last residue of dissolving in the lithodialysis agent of cholelithiasis sample, and wherein upper figure is the cholelithiasis sample spectra, and figure below is the infrared spectrum of last residue after the dissolving.Two spectrum peaks have than big difference, and the main component in the cholesterol type calculus sample is described, namely cholesterol is substantially dissolved, the residue that remainder can not be dissolved by the lithodialysis agent.
By in the ultrared spectrum storehouse to the infrared spectrum matching ratio of residue pair, find the infrared spectrum and bilirubinic spectrogram matching degree maximum of residue.Once reported in the pertinent literature that the main component in people's cholelithiasis was cholesterol and bilirubin, and cholesterol level surpasses 70% in the cholesterol type calculus, have in addition up to more than 90%.Therefore, the lithodialysis agent of this embodiment of the invention preparation is better for the litholytic effect of cholesterol type calculus.
Form photo after this cholelithiasis is fully dissolved by the agent of lithodialysis that prepared as shown in Figure 5, visible cholelithiasis is dissolved substantially.
Embodiment 3:
The agent of preparation lithodialysis:
This relation preparation lithodialysis agent of soybean lecithin according to the corresponding 1.20g of the methyl tert-butyl ether of 3mL.
The dissolving human gallstones:
Get a cholesterol type cholelithiasis sample from human body as embodiment 2.This cholelithiasis sample is added in the lithodialysis agent of preparing gradually, and ultrasonic lower, cholelithiasis is dissolved substantially after 12 to 13min, only stays a small amount of insoluble residue, and similar Fig. 5 is such for its form photo, and the diameter of these residues is basically less than 1mm.
Embodiment 4:
The agent of preparation lithodialysis:
In order to measure at the appointed time, the different lithodialysis agent of Ovum Gallus domesticus Flavus lecithin amount is to the solvability of cholesterol, the methyl tert-butyl ether that adds respectively 3mL in the color-comparison tube of 6 10mL, add respectively again 0.00g, 0.30g, 0.60g, 0.90g, 1.20g the Ovum Gallus domesticus Flavus lecithin of 1.50g is made solution.
Dissolving cholesterol:
Add gradually cholesterol in these 6 test tubes, vortex oscillation was calculated respectively the meltage of cholesterol after 3 minutes.
Experimental result:
Listed in the table 2 and increased the dissolving situation of cholesterol in this lithodialysis agent along with the Ovum Gallus domesticus Flavus lecithin amount.
Table 2:
| The amount of methyl tert-butyl ether (mL) | 3 | 3 | 3 | 3 | 3 | 3 |
| The amount of Ovum Gallus domesticus Flavus lecithin (g) | 0.00 | 0.30 | 0.60 | 0.90 | 1.20 | 1.50 |
| The amount of dissolving cholesterol (g) | 0.42 | 0.68 | 0.69 | 0.70 | 0.73 | 0.86 |
Can find out from the experimental result of table 2, content along with Ovum Gallus domesticus Flavus lecithin in the lithodialysis agent increases, the amount of dissolving cholesterol increases gradually, even when the mass penalty of Ovum Gallus domesticus Flavus lecithin during to 1.5g, the meltage of cholesterol in the lithodialysis agent is still larger, but observe this moment solution system viscosity also larger.
Embodiment 5:
The agent of preparation lithodialysis:
This relation preparation lithodialysis agent of Ovum Gallus domesticus Flavus lecithin according to the corresponding 0.30g of the methyl tert-butyl ether of 3mL.
The dissolving human gallstones:
Get a cholelithiasis sample that from human body, takes out, determine that by infrared spectrogram this sample is the cholesterol type calculus.Form photo before this cholelithiasis is dissolved by the lithodialysis agent as described in Figure 6.
This cholelithiasis sample is added in the lithodialysis agent of preparing gradually, and ultrasonic lower, cholelithiasis is dissolved substantially after 18 to 20min, only stays a small amount of insoluble residue.By in the ultrared spectrum storehouse to the infrared spectrum matching ratio of residue pair, find the infrared spectrum and bilirubinic spectrogram matching degree maximum of residue.Therefore, this lithodialysis agent is better for the litholytic effect of cholesterol type calculus.
Form photo after this cholelithiasis is fully dissolved by the agent of lithodialysis that prepared as shown in Figure 7, visible cholelithiasis is dissolved substantially, and the diameter of these residues is basically less than 1mm.
Embodiment 6:
The agent of preparation lithodialysis:
This relation preparation lithodialysis agent of Ovum Gallus domesticus Flavus lecithin according to the corresponding 0.90g of the methyl tert-butyl ether of 3mL.
The dissolving human gallstones:
Get a cholesterol type cholelithiasis sample from human body as embodiment 5.This cholelithiasis sample is added in the lithodialysis agent of preparing gradually, and ultrasonic lower, cholelithiasis is dissolved substantially after 16 to 17min, only stays a small amount of insoluble residue, and similar Fig. 7 is such for its form photo, and the diameter of these residues is basically less than 1mm.
Embodiment 7:
The agent of preparation lithodialysis:
This relation preparation lithodialysis agent of Ovum Gallus domesticus Flavus lecithin according to the corresponding 1.50g of the methyl tert-butyl ether of 3mL.
The dissolving human gallstones:
Get a cholesterol type cholelithiasis sample from human body as embodiment 5.This cholelithiasis sample is added in the lithodialysis agent of preparing gradually, and ultrasonic lower, cholelithiasis is dissolved substantially after 14 to 15min, only stays a small amount of insoluble residue, and similar Fig. 7 is such for its form photo, and the diameter of these residues is basically less than 1mm.
Test case:
Carbon spectrum: in the cholesterol of the methyl tertiary butyl ether(MTBE) of Fig. 8 a and Fig. 8 b with the carbon atom of asterisk * as object of study.
Steps A:In MTBE, add abundant cholesterol, fully get a certain amount of supernatant after the dissolving and dilute with MTBE, the solution after the dilution is carried out the mensuration of quantitative carbon spectrum.Area with the corresponding peak of the carbon atom of asterisk * in Fig. 8 a methyl tert-butyl ether is decided to be 1, and with the area at nuclear-magnetism spectrum peak corresponding to the carbon atom of asterisk *, this called after b peak, peak is shown in Fig. 8 c figure below in the cholesterol of survey map 8b.
Step B:Add abundant cholesterol in the lithodialysis agent of soybean lecithin that embodiment 2 prepares and MTBE, fully get a certain amount of supernatant after the dissolving, with the MTBE dilution, extension rate is 1.3 times of steps A, the solution after the dilution is carried out the mensuration of quantitative carbon spectrum.Area with the corresponding peak of the carbon atom of asterisk * in the methyl tert-butyl ether of Fig. 8 a is decided to be 1, and with the area at the corresponding peak of carbon atom of asterisk *, this called after a peak, peak is shown in the upper figure of Fig. 8 c in the cholesterol of survey map 8b.
Because after in the lithodialysis agent of soybean lecithin and MTBE formation, dissolving more cholesterol, long-term placement system can be solidified, be unfavorable for doing quantitative carbon spectrum (because quantitatively long time of carbon spectrum needs scanning), so for the A step, the dilution that system has been carried out a little times.After conversion, the integral area at a peak is that the integral area at 0.048, b peak is 0.041 among Fig. 8 c.Therefore, by quantitative carbon spectrum further verified in MTB E, add soybean lecithin after, mixed solvent further increases the solvability of cholesterol.And by the nuclear-magnetism graph discovery, after in MTB E, adding soybean lecithin, movement has occured to High-Field in the peak position of cholesterol, illustrate to exist certain interaction force between soybean lecithin and the cholesterol, and this active force may be to cause novel lithodialysis agent to the immediate cause of the solvability increase of cholesterol.
Step B ':In the lithodialysis agent of Ovum Gallus domesticus Flavus lecithin that embodiment 5 prepares and MTB E, add abundant cholesterol, fully get a certain amount of supernatant after the dissolving, with the MTB E dilution multiple identical with steps A, the solution after the dilution is carried out the mensuration that quantitative carbon is composed.Area with the corresponding peak of the carbon atom of asterisk * in the methyl tert-butyl ether of Fig. 8 a is decided to be 1, and with the area at the corresponding peak of carbon atom of asterisk *, this called after a peak, peak is shown in the upper figure of Fig. 8 d in the cholesterol of survey map 8b.
The integral area at a peak is that the integral area at 0.054, b peak is 0.041 among Fig. 8 d.Therefore, by quantitative carbon spectrum further verified in MTB E, add Ovum Gallus domesticus Flavus lecithin after, mixed solvent further increases the solvability of cholesterol.And by the nuclear-magnetism graph discovery, after in MTBE, adding Ovum Gallus domesticus Flavus lecithin, movement has occured to High-Field in the peak position of cholesterol, illustrate to exist certain interaction force between Ovum Gallus domesticus Flavus lecithin and the cholesterol, and this active force may be to cause novel lithodialysis agent to the immediate cause of the solvability increase of cholesterol.
More than by the preferred specific embodiment the present invention has been carried out exemplary explanation.What but need statement is; these specific embodiment only are to illustrative explanation of the present invention; protection scope of the present invention is not consisted of any restriction; in the situation that does not exceed the present invention's spirit and protection domain; those skilled in the art can carry out various improvement, the of equal value replacement or modification to the technology of the present invention content and embodiment thereof, and these all fall within the scope of protection of the present invention.
Claims (7)
1. a mixing lithodialysis agent that is used for dissolving cholesterol type calculus is characterized in that,
This lithodialysis agent comprises methyl tert-butyl ether and lecithin, described lecithin is soybean lecithin or Ovum Gallus domesticus Flavus lecithin, and based on the methyl tert-butyl ether meter of 1mL, the amount of soybean lecithin is 0.30～0.40g, perhaps based on the methyl tert-butyl ether meter of 1mL, the amount of Ovum Gallus domesticus Flavus lecithin is 0.10～0.40g.
2. lithodialysis agent according to claim 1 is characterized in that, described lecithin is soybean lecithin.
3. lithodialysis agent according to claim 1 is characterized in that, described lecithin is Ovum Gallus domesticus Flavus lecithin.
4. lithodialysis agent according to claim 1 is characterized in that,
Based on the methyl tert-butyl ether meter of 1mL, the amount of soybean lecithin is 0.30g.
5. lithodialysis agent according to claim 2 is characterized in that,
Based on the methyl tert-butyl ether meter of 1mL, the amount of soybean lecithin is 0.30g.
6. according to claim 1 to one of 5 described lithodialysis agent, it is characterized in that described lithodialysis agent is comprised of the methyl tert-butyl ether of described amount and soybean lecithin or Ovum Gallus domesticus Flavus lecithin.
7. according to claim 1 to the purposes of one of 6 described lithodialysis agent in the medicine of preparation treatment cholesterol type calculus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210065192 CN102614155B (en) | 2012-01-13 | 2012-01-13 | Mixed litholytic agent for dissolving cholesterol stone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210065192 CN102614155B (en) | 2012-01-13 | 2012-01-13 | Mixed litholytic agent for dissolving cholesterol stone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102614155A CN102614155A (en) | 2012-08-01 |
| CN102614155B true CN102614155B (en) | 2013-10-16 |
Family
ID=46554609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210065192 Expired - Fee Related CN102614155B (en) | 2012-01-13 | 2012-01-13 | Mixed litholytic agent for dissolving cholesterol stone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102614155B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4758596A (en) * | 1984-04-10 | 1988-07-19 | Research Corporation | Method for therapeutic use of methyl tertiary-butyl ether |
| CN1123269A (en) * | 1994-11-19 | 1996-05-29 | 浙江九洲制药厂 | Method for preparation of ethyl tert-butyl ether and prdouct thereof and application thereof |
-
2012
- 2012-01-13 CN CN 201210065192 patent/CN102614155B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4758596A (en) * | 1984-04-10 | 1988-07-19 | Research Corporation | Method for therapeutic use of methyl tertiary-butyl ether |
| CN1123269A (en) * | 1994-11-19 | 1996-05-29 | 浙江九洲制药厂 | Method for preparation of ethyl tert-butyl ether and prdouct thereof and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102614155A (en) | 2012-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Akaneme | Identification and preliminary phytochemical analysis of herbs that can arrest threatened miscarriage in Orba and Nsukka towns of Enugu State | |
| AU2016349516A1 (en) | Treatments of accumulated fat with deoxycholic acid and salts thereof | |
| CN105998972A (en) | Bacteriostatic gel | |
| US20030229029A1 (en) | Cardiac glycosides for treating muscle pain and spasm | |
| Willer et al. | Ethnopharmacology, phytochemistry, and bioactivities of Hieracium L. and Pilosella Hill (Cichorieae, Asteraceae) species | |
| US20070249543A1 (en) | Dissolution of arterial cholesterol plaques by phytochemical emulsifiers | |
| CN102614155B (en) | Mixed litholytic agent for dissolving cholesterol stone | |
| CN102641338B (en) | Massage medicament for treating soft tissue injury | |
| CN101492489B (en) | Method for extracting anemonin A and method of preparing lipid microsphere preparation | |
| CN102626402B (en) | Monolauryl phosphate-containing lithontriptic for litholysis of cholesterol gallstone | |
| CN105125708B (en) | A kind of pharmaceutical composition and preparation method thereof for rhinitis | |
| CN101081256A (en) | Medicine having good function of treating eye disease | |
| CN100571727C (en) | Direct lytic agent of a kind of Chinese medicine compound cholelithiasis and preparation method thereof | |
| CN103356971A (en) | Traditional Chinese medicine composition capable of substantially improving human immunity and preparation method thereof | |
| CN108066681A (en) | It is a kind of for mongolian medicine patch of infantile hyperpyrexia and preparation method thereof and application method | |
| CN107158093A (en) | A kind of external application hot compress preparation for treating lumbar vertebrae hyperosteogeny | |
| CN103720750B (en) | A kind of Chinese medicine preparation and preparation method thereof | |
| CN109568419A (en) | A kind of Morinda officinalis total iridoid glycoside and its preparation method and application | |
| CN108404094A (en) | A kind of thin network analgesic antiphlogistic bee venom application conditioning cream | |
| CN103585330B (en) | A kind of Chinese medicine composition for cutaneous fungal infection and preparation method thereof | |
| CN107375496A (en) | A kind of pharmaceutical composition and preparation method thereof with removing damp-heat, the antipruritic function of desinsection | |
| KR20080105857A (en) | A composite, its manufacturing process and medication for healing hemorrhoids | |
| CN105687350A (en) | Traditional Chinese medicine composition for treating ischemic cerebral apoplexy and application thereof | |
| CN101375948B (en) | External-use formulation for impotence and preparation method thereof | |
| CN105326879A (en) | Fatty acid extract of rape pollen as well as preparation method and application of fatty acid extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131016 Termination date: 20170113 |